Dabigatran Etexilate Mesylate (CAS 872728-81-9)
QUICK LINKS
Dabigatran Etexilate Mesylate is a compound that is widely utilized in biochemical research. In the laboratory, this compound is of interest due to its role as a prodrug that, upon metabolic conversion, releases dabigatran, an active molecule that inhibits thrombin. Research on Dabigatran Etexilate Mesylate primarily focuses on understanding its biotransformation and the kinetics of its active metabolites. Studies involve the investigation of its absorption, distribution, metabolism, and excretion (ADME) properties, which are critical for predicting the behavior of related compounds. Additionally, it is used to examine the effect of various biological factors on its conversion to the active inhibitor. The mesylate salt form is particularly suitable for such studies as it enhances the solubility of the compound, facilitating its use in various experimental setups. Researchers may also utilize Dabigatran Etexilate Mesylate to develop and validate analytical methods for detecting and quantifying the prodrug and its metabolites in biological samples.
Dabigatran Etexilate Mesylate (CAS 872728-81-9) References
- New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate. | Hussar, DA. and Zimmerman, DE. 2011. J Am Pharm Assoc (2003). 51: 122-6. PMID: 21247838
- Extensive postoperative ecchymosis in a patient taking dabigatran. | Wagner, CA., et al. 2013. J Minim Invasive Gynecol. 20: 127-30. PMID: 23312256
- Case report series of left atrial thrombus formation in patients on dabigatran therapy. | Sharma, S., et al. 2014. Am J Ther. 21: e71-4. PMID: 23803980
- New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. | Chatterjee, S., et al. 2013. JAMA Neurol. 70: 1486-90. PMID: 24166666
- Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. | Bapat, P., et al. 2014. Obstet Gynecol. 123: 1256-1261. PMID: 24807346
- Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form. | Anumolu, PD., et al. 2016. Indian J Pharm Sci. 78: 166-9. PMID: 27168697
- Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. | Sunkara, T., et al. 2016. Health Serv Insights. 9: 25-36. PMID: 28008269
- Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage. | Balakumar, J., et al. 2017. Clin Pract Cases Emerg Med. 1: 349-353. PMID: 29849330
- Generic approach in a gradient elution HPLC method development that enables troubleshooting free method transfer. | Milenković, M., et al. 2022. J Pharm Biomed Anal. 207: 114367. PMID: 34607169
- Development and validation of a ultraperformance liquid chromatography-tandem mass spectrometry method for quantifying free and total dabigatran in human plasma: An application for a bioequivalence study. | Abd Allah, FI., et al. 2022. Biomed Chromatogr. 36: e5382. PMID: 35389511
- Medications mostly associated with hematuria: assessment of the EudraVigilance and Food and Drug Administration pharmacovigilance databases entries. | Cicione, A., et al. 2023. Minerva Urol Nephrol.. PMID: 36662230
- The polymorph landscape of Dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market. | Sieger, P., et al. 2023. Eur J Pharm Sci. 106447. PMID: 37044200
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dabigatran Etexilate Mesylate, 10 mg | sc-500661 | 10 mg | $151.00 | |||
Dabigatran Etexilate Mesylate, 100 mg | sc-500661A | 100 mg | $297.00 | |||
Dabigatran Etexilate Mesylate, 250 mg | sc-500661B | 250 mg | $442.00 | |||
Dabigatran Etexilate Mesylate, 500 mg | sc-500661C | 500 mg | $577.00 | |||
Dabigatran Etexilate Mesylate, 1 g | sc-500661D | 1 g | $774.00 | |||
Dabigatran Etexilate Mesylate, 10 g | sc-500661E | 10 g | $2502.00 |